Abnormal liver function on admission predicts severe outcomes in COVID-19 patients: a multicenter study (Preprint)

Xiu-Ping Zhang,Jiong Yu,Haibo Li,Wenquan Liang,Wentao Ni,Hongcui Cao,Rong Liu,Jie Liu,Lanjuan Li

DOI: https://doi.org/10.2196/preprints.23007

2020-01-01

Abstract:BACKGROUND Coronavirus disease 2019 (COVID-19) is a new infectious disease. Patients with mild COVID-19 have abnormal liver function at first blood examination upon admission.However, the association of abnormal liver function at admission in COVID-19 patients with severe outcomes is unclear. OBJECTIVE We aimed to elucidate the relationship between early abnormal liver function and COVID-19 severity. METHODS In this multicenter retrospective cohort study, patients with COVID-19 admitted to the 42 hospitals in Zhejiang province were enrolled. Clinical and pathological data of these patients were retrospectively analyzed. RESULTS A total of 963 patients meeting the inclusion criteria with mild COVID-19 on admission were enrolled. The occurrence of severe outcomes positively correlated with elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (TB) (P<0.001, P<0.008, and P=0.053, respectively). The probabilities of severe outcomes in patients with normal AST, ALT and TB levels were 13%, 21.3%, and 6.1%, respectively. In contrast, the probabilities were 34.8%, 34.8%, and 26.1%, respectively, in patients with elevated levels of injury indicators. After adjusting for confounding factors, in contrast to patients without liver dysfunction, patients with elevated AST, ALT and TB tended to have a higher risk of severe outcomes [HR (95% CI): 2.82 (1.49,5.35), 2.05 (1.08,3.88) and 3.21 (1.58,6.55), respectively]. CONCLUSIONS This study found for the first time that abnormal liver function in COVID-19 patients on admission was related to severe outcomes. Clinicians should closely monitor and pay attention to changes in patients’ conditions to prevent the occurrence of severe outcomes.